Acipimox

Jump to: navigation, search
Acipimox
Skeletal formula
Ball-and-stick model
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC6H6N2O3
Molar mass154.124 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Acipimox

Articles

Most recent articles on Acipimox

Most cited articles on Acipimox

Review articles on Acipimox

Articles on Acipimox in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Acipimox

Images of Acipimox

Photos of Acipimox

Podcasts & MP3s on Acipimox

Videos on Acipimox

Evidence Based Medicine

Cochrane Collaboration on Acipimox

Bandolier on Acipimox

TRIP on Acipimox

Clinical Trials

Ongoing Trials on Acipimox at Clinical Trials.gov

Trial results on Acipimox

Clinical Trials on Acipimox at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Acipimox

NICE Guidance on Acipimox

NHS PRODIGY Guidance

FDA on Acipimox

CDC on Acipimox

Books

Books on Acipimox

News

Acipimox in the news

Be alerted to news on Acipimox

News trends on Acipimox

Commentary

Blogs on Acipimox

Definitions

Definitions of Acipimox

Patient Resources / Community

Patient resources on Acipimox

Discussion groups on Acipimox

Patient Handouts on Acipimox

Directions to Hospitals Treating Acipimox

Risk calculators and risk factors for Acipimox

Healthcare Provider Resources

Symptoms of Acipimox

Causes & Risk Factors for Acipimox

Diagnostic studies for Acipimox

Treatment of Acipimox

Continuing Medical Education (CME)

CME Programs on Acipimox

International

Acipimox en Espanol

Acipimox en Francais

Business

Acipimox in the Marketplace

Patents on Acipimox

Experimental / Informatics

List of terms related to Acipimox

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout.

References


Linked-in.jpg